PTC Therapeutics, Inc. Financing Cash Flow
PTC Therapeutics, Inc. (PTCT) reported Financing Cash Flow of $218.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-30
- PTC Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $211.88M, a 5249.10% increase year-over-year.
- PTC Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $6.40M, a 31.96% decline year-over-year.
- PTC Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $302.50M, a 1042.78% increase year-over-year.
- PTC Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $15.22M.
- PTC Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $331.09M, a 29.40% increase from fiscal 2024.
- PTC Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $255.87M, a 60.42% decline from fiscal 2023.
- PTC Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $646.40M, a 284.87% increase from fiscal 2022.
- PTC Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $167.95M, a 704.48% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $211.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $218.28M 10-Q · filed 2026-07-30 | $520.78M derived: sum of 3 quarters · filed 2026-07-30 | $536.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $6.40M 10-Q · filed 2026-05-07 | $308.91M derived: sum of 2 quarters · filed 2026-05-07 | $324.13M derived: sum of 3 quarters · filed 2026-05-07 | $328.09M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $302.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $317.72M derived: sum of 2 quarters · filed 2026-02-19 | $321.68M derived: sum of 3 quarters · filed 2026-07-30 | $331.09M 10-K · filed 2026-02-19 |
| 2025-09-30 | $15.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $19.18M derived: sum of 2 quarters · filed 2026-07-30 | $28.59M 10-Q · filed 2025-11-04 | $55.06M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $13.37M 10-Q · filed 2026-07-30 | $39.84M derived: sum of 3 quarters · filed 2026-07-30 | $22.21M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $9.41M 10-Q · filed 2026-05-07 | $35.88M derived: sum of 2 quarters · filed 2026-05-07 | $18.25M derived: sum of 3 quarters · filed 2026-05-07 | $264.74M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $26.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $8.84M derived: sum of 2 quarters · filed 2026-02-19 | $255.33M derived: sum of 3 quarters · filed 2026-02-19 | $255.87M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$17.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $228.85M derived: sum of 2 quarters · filed 2025-11-04 | $229.40M 10-Q · filed 2025-11-04 | $849.88M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $246.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $247.02M 10-Q · filed 2025-08-07 | $867.51M derived: sum of 3 quarters · filed 2026-02-19 | $870.87M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $540.00K 10-Q · filed 2025-05-06 | $621.02M derived: sum of 2 quarters · filed 2026-02-19 | $624.39M derived: sum of 3 quarters · filed 2026-02-19 | $642.85M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $620.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $623.85M derived: sum of 2 quarters · filed 2026-02-19 | $642.31M derived: sum of 3 quarters · filed 2026-02-19 | $646.40M 10-K · filed 2026-02-19 |
| 2023-09-30 | $3.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $21.82M derived: sum of 2 quarters · filed 2024-11-07 | $25.91M 10-Q · filed 2024-11-07 | $328.83M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $18.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $22.55M 10-Q · filed 2024-08-08 | $325.47M derived: sum of 3 quarters · filed 2025-02-27 | $185.48M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $4.09M 10-Q · filed 2024-04-25 | $307.01M derived: sum of 2 quarters · filed 2025-02-27 | $167.02M derived: sum of 3 quarters · filed 2025-02-27 | $170.88M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $302.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $162.92M derived: sum of 2 quarters · filed 2025-02-27 | $166.78M derived: sum of 3 quarters · filed 2025-02-27 | $167.95M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$140.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | -$136.13M derived: sum of 2 quarters · filed 2023-10-26 | -$134.97M 10-Q · filed 2023-10-26 | -$130.61M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $3.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $5.03M 10-Q · filed 2023-08-03 | $9.38M derived: sum of 3 quarters · filed 2024-02-29 | $12.36M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.17M 10-Q · filed 2023-04-27 | $5.52M derived: sum of 2 quarters · filed 2024-02-29 | $8.50M derived: sum of 3 quarters · filed 2024-02-29 | $12.51M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $7.33M derived: sum of 2 quarters · filed 2024-02-29 | $11.35M derived: sum of 3 quarters · filed 2024-02-29 | $20.88M 10-K · filed 2024-02-29 |
| 2021-09-30 | $2.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $6.99M derived: sum of 2 quarters · filed 2022-10-27 | $16.52M 10-Q · filed 2022-10-27 | $56.61M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $4.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $13.55M 10-Q · filed 2022-08-04 | $53.64M derived: sum of 3 quarters · filed 2023-02-21 | $696.69M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $9.53M 10-Q · filed 2022-05-03 | $49.62M derived: sum of 2 quarters · filed 2023-02-21 | $692.67M derived: sum of 3 quarters · filed 2023-02-21 | $659.76M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $40.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $683.14M derived: sum of 2 quarters · filed 2023-02-21 | $650.23M derived: sum of 3 quarters · filed 2023-02-21 | $668.72M 10-K · filed 2023-02-21 |
| 2020-09-30 | $643.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $610.14M derived: sum of 2 quarters · filed 2021-10-28 | $628.63M 10-Q · filed 2021-10-28 | $630.91M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | -$32.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$14.43M 10-Q · filed 2021-07-29 | -$12.14M derived: sum of 3 quarters · filed 2022-02-22 | $370.21M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $18.49M 10-Q · filed 2021-05-04 | $20.77M derived: sum of 2 quarters · filed 2022-02-22 | $403.13M derived: sum of 3 quarters · filed 2022-02-22 | $405.98M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $384.64M derived: sum of 2 quarters · filed 2022-02-22 | $387.49M derived: sum of 3 quarters · filed 2022-02-22 | $613.21M 10-K · filed 2022-02-22 |
| 2019-09-30 | $382.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $385.20M derived: sum of 2 quarters · filed 2020-10-29 | $610.92M 10-Q · filed 2020-10-29 | $614.65M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $228.57M 10-Q · filed 2020-08-05 | $232.30M derived: sum of 3 quarters · filed 2021-02-25 | $237.38M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $225.72M 10-Q · filed 2020-04-30 | $229.45M derived: sum of 2 quarters · filed 2021-02-25 | $234.53M derived: sum of 3 quarters · filed 2021-02-25 | $356.16M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $8.81M derived: sum of 2 quarters · filed 2021-02-25 | $130.44M derived: sum of 3 quarters · filed 2021-02-25 | $131.57M 10-K · filed 2021-02-25 |
| 2018-09-30 | $5.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $126.71M derived: sum of 2 quarters · filed 2019-10-30 | $127.84M 10-Q · filed 2019-10-30 | $129.70M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $121.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $122.77M 10-Q · filed 2019-08-06 | $124.62M derived: sum of 3 quarters · filed 2020-03-02 | $126.32M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $1.14M 10-Q · filed 2019-05-02 | $2.99M derived: sum of 2 quarters · filed 2020-03-02 | $4.69M derived: sum of 3 quarters · filed 2020-03-02 | $44.69M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $3.56M derived: sum of 2 quarters · filed 2020-03-02 | $43.55M derived: sum of 3 quarters · filed 2020-03-02 | $44.22M 10-K · filed 2020-03-02 |
| 2017-09-30 | $1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $41.70M derived: sum of 2 quarters · filed 2018-11-05 | $42.37M 10-Q · filed 2018-11-05 | $42.41M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $40.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $40.66M 10-Q · filed 2018-08-07 | $40.70M derived: sum of 3 quarters · filed 2019-03-01 | $41.59M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $663.00K 10-Q · filed 2018-05-09 | $705.00K derived: sum of 2 quarters · filed 2019-03-01 | $1.60M derived: sum of 3 quarters · filed 2019-03-01 | |
| 2016-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $934.00K derived: sum of 2 quarters · filed 2019-03-01 | $968.00K 10-K · filed 2019-03-01 | |
| 2016-09-30 | $892.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $926.00K 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | $34.00K 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $154.06M 10-K · filed 2018-03-06 | |||
| 2014-12-31 | $237.13M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |